SCHEDULE 13G/A 0001104659-24-082776 0001738048 XXXXXXXX LIVE 1 Ordinary shares, par value US$0.0001 12/31/2025 0001962738 CASI Pharmaceuticals, Inc. G1933S101 1701-1702, China Central Office Tower 1 No. 81 Jianguo Road, Chaoyang District Beijing F4 100025 Rule 13d-1(c) Venrock Healthcare Capital Partners III, L.P. a DE 0.00 1987259.00 0.00 1987259.00 1987259.00 9.2 PN VHCP Co-Investment Holdings III, LLC a DE 0.00 1987259.00 0.00 1987259.00 1987259.00 9.2 OO Venrock Healthcare Capital Partners EG, L.P. a DE 0.00 1987259.00 0.00 1987259.00 1987259.00 9.2 PN VHCP Management III, LLC a DE 0.00 1987259.00 0.00 1987259.00 1987259.00 9.2 OO VHCP Management EG, LLC a DE 0.00 1987259.00 0.00 1987259.00 1987259.00 9.2 OO Nimish Shah a X1 0.00 1987259.00 0.00 1987259.00 1987259.00 9.2 IN Bong Y. Koh a X1 0.00 1987259.00 0.00 1987259.00 1987259.00 9.2 IN CASI Pharmaceuticals, Inc. 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, F4, 100025. The names of the persons filing this report (collectively, the "Reporting Persons") are: Venrock Healthcare Capital Partners III, L.P. ("VHCP III") VHCP Co-Investment Holdings III, LLC ("VHCP Co-Investment III") Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG") VHCP Management III, LLC ("VHCP Management III") VHCP Management EG, LLC ("VHCP Management EG") Nimish Shah ("Shah") Bong Koh ("Koh") The Reporting Persons are members of a group for the purposes of this Schedule 13G/A. New York Office: 7 Bryant Park, 23rd Floor New York, NY 10018 Palo Alto Office: 3340 Hillview Avenue Palo Alto, CA 94304 All of the entities were organized in Delaware. Shah and Koh are both United States citizens. Y Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of ordinary shares of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) 159,359 ordinary shares and pre-funded warrants (the "Pre-Funded Warrants") exercisable for up to 159,100 ordinary shares held by VHCP III, (ii) 15,923 ordinary shares and Pre-Funded Warrants exercisable for up to 15,900 ordinary shares held by VHCP Co-Investment III, and (iii) 811,977 ordinary shares and Pre-Funded Warrants exercisable for up to 825,000 ordinary shares held by VHCP EG. VHCP Management III is the general partner of VHCP III and the manager of VHCP Co-Investment III. VHCP Management EG is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCP Management III and VHCP Management EG. Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the ordinary shares of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. The percentage set forth in each row 11 is based upon the sum of (i) 20,548,273 outstanding ordinary shares as of September 30, 2025, as reported in the Issuer's Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission (the "SEC") on November 14, 2025 and (ii) 1,000,000 ordinary shares issuable upon the exercise of the Pre-Funded Warrants. Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 24.1 Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on July 25, 2024) Exhibit 24.2 Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed on July 25, 2024) Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on July 25, 2024) Venrock Healthcare Capital Partners III, L.P. /s/ Sherman G. Souther 02/17/2026 VHCP Co-Investment Holdings III, LLC /s/ Sherman G. Souther 02/17/2026 Venrock Healthcare Capital Partners EG, L.P. /s/ Sherman G. Souther 02/17/2026 VHCP Management III, LLC /s/ Sherman G. Souther 02/17/2026 VHCP Management EG, LLC /s/ Sherman G. Souther 02/17/2026 Nimish Shah /s/ Sherman G. Souther 02/17/2026 Bong Y. Koh /s/ Sherman G. Souther 02/17/2026